

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/644,976	08/21/2003	Shouhei Kozakai	0171-1012P	6358	
2292	7590 09/06/2006	i	EXAM	EXAMINER	
	EWART KOLASCH	PENG, KU	PENG, KUO LIANG		
PO BOX 74 FALLS CH	/ URCH, VA 22040-07	<b>4</b> 7	ART UNIT	PAPER NUMBER	
,			1712	<u> </u>	
			DATE MAILED: 09/06/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)			
	10/644,976	KOZAKAI ET AL.			
Office Action Summary	Examiner	Art Unit			
	Kuo-Liang Peng	1712			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I.  lely filed  the mailing date of this communication.  (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 6/16/	06 Amendment.				
,					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the m					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.			
Disposition of Claims					
<ul> <li>4)  Claim(s) 1 and 4-19 is/are pending in the application 4a) Of the above claim(s) is/are withdraw</li> <li>5)  Claim(s) 1 and 4-8 is/are allowed.</li> <li>6)  Claim(s) 9,11-16,18 and 19 is/are rejected.</li> <li>7)  Claim(s) 10 and 17 is/are objected to.</li> <li>8)  Claim(s) are subject to restriction and/or</li> </ul>	vn from consideration.	·			
Application Papers					
9)⊠ The specification is objected to by the Examine 10)☐ The drawing(s) filed on is/are: a)☐ acceedable.  Applicant may not request that any objection to the objection to the objection is the objection is the objection in the objection is the objection is the objection in the objection is the objection in the objection is objected to by the Examine is objected to be objec	epted or b) objected to by the Edrawing(s) be held in abeyance. See	e 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correcting 11) The oath or declaration is objected to by the Ex					
Priority under 35 U.S.C. § 119					
a) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attachment(s)  1)   Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO-413)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da				

Application/Control Number: 10/644,976 Page 2

Art Unit: 1712

#### **DETAILED ACTION**

1. The Applicants' amendment filed on June 16, 2006 was received. Claims 1, 6 and 9-11 are amended. Claims 2-3 are deleted. Now, Claims 1 and 4-19 are pending.

- 2. Claim rejection(s) under double patenting rejection in the previous Office Action (Paper No. 031406) is/are removed.
- 3. The text of those sections of Title 35, U.S. code not included in this action can be found in prior Office Action(s).

## Specification

4. Applicant is reminded of the proper language and format for an abstract of the disclosure.

The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words. It is important that the abstract not exceed 150 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The **form and legal phraseology** often used in patent claims, such as "means" and "said," should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details.

Application/Control Number: 10/644,976

Art Unit: 1712

The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc.

The word "comprising" in the first line of the abstract is improper.

#### Claim Rejections - 35 USC § 112

5. Claims 1, 4-8 and 18 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In Claim 1 (page 3, line 3), Claim 6 (page 4, line 11) and Claim 18 (page 11, line, the phrase "alkenyl radicals in components (A) and (B)" causes confusion because components (A) and (B) do not necessarily contain alkenyl radicals. Note that, for Claims 1 and 6, the only place where components (A) and (B) contain alkenyl radicals is the component (B) which can be a silane or siloxane compound having both Si-alkoxy and Si-alkenyl *or* Si-H. (Emphasis added) As such, the alkenyl radicals are even not necessarily present in this particular component (B). For Claim 18, none of components (A) and (B) contain alkenyl radicals. Should the specific alkyl radicals, aryl radicals and **alkenyl** radicals for R<sup>1</sup> and R<sup>2</sup> described in the specification (page 5, 2<sup>nd</sup> paragraph) be explicitly cited in component (A) of the

Application/Control Number: 10/644,976

Art Unit: 1712

instant claims so that when component (B) does not contain alkenyl radicals, component (A) will contain alkenyl radicals?

Claim 18 recites the limitation "alkenyl radicals" in page 11, line 1. There is insufficient antecedent basis for this limitation in the claim.

- 6. The following is a quotation of the first paragraph of 35 U.S.C. 112:
  - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 7. Claims 16 and 18-19 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the use of the **specific** organosilane or organosiloxane-modified isocyanurate compounds set forth in page 9, lines 1-3, does not reasonably provide enablement for the use of **any** organosilane or organosiloxane-modified isocyanurate compounds. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

Application/Control Number: 10/644,976 Page 5

Art Unit: 1712

#### Claim Rejections - 35 USC § 103

8. Claims 9 and 11-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Aoki (US 2002/0013386) in view of Cifuentes (US 5 508 360).

Aoki in view of Cifuentes discloses a silicone adhesive as described in paragraph 5 of the prior Office action (Paper No. 042205), which renders the instant claims unpatentable because a **silane** compound containing Si-alkoxy group and Si-epoxy group is taught.

9. Claims 16 and 18-19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Aoki (US 2002/0013386) in view of Dalbe (WO 00/32694).

The following column and line numbers of Dalbe are based on its U.S. equivalent (US 6 777 471).

Akoi discloses a silicone adhesive as described in the prior Office actions.

Aoki is silent on the use of an organosiloxane-modified isocyanurate compound set forth in the instant claims. However, Dalbe teaches the use of trimethoxysilylpropyl isocyanurate in an adhesive composition derived from a mixture comprising a hydroxyl group end-capped polyorganosiloxane, an MQ resin containing hydroxyl groups. The motivation is to enhance the adhesion of the composition to a substrate. (col. 1, line 66 to col. 5, line 6, col. 7, line 52 to col. 8,

Art Unit: 1712

line 10 and Examples) In light of the benefit mentioned, it would have been obvious to one of ordinary skill in the art at the time of the invention was made to incorporate Dalbe's trimethoxysilylpropyl isocyanurate into Akoi's adhesive. Especially, Dalbe is in the same field of that of Akoi's endeavor.

10. Claims 10 and 17 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

None of Aoki (US 2002/0013386), Clifentes (US 5 508 360), Fujita (US 2002/0086942), Ushizaka (US 5 415 912) and Dalbe, taken alone or in combination, teaches or fairly suggests the specific component (B) set forth in the instant claims.

### Allowable Subject Matter

- 11. Claims 1 and 4-8 are allowed.
- 12. The following is an examiner's statement of reasons for allowance:

None of Aoki (US 2002/0013386), Clifentes (US 5 508 360), Fujita (US 2002/0086942), Ushizaka (US 5 415 912) and Dalbe, taken alone or in

combination, teaches or fairly suggests the specific component (C) set forth in the instant claims.

Any inquiry concerning this communication or earlier communications from 13. the examiner should be directed to Kuo-Liang Peng whose telephone number is (571) 272-1091. The examiner can normally be reached on Monday-Friday from 8:30 AM to 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Randy Gulakowski, can be reached on (571) 272-1302. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

klp

August 28, 2006

Kuo-Liang Peng Primary Examiner Art Unit 1712 Page 8